Adjuvant immunotherapy in patients with high‐risk muscle‐invasive urothelial carcinoma: The potential impact of informative censoring
Alberto Martini(The University of Texas MD Anderson Cancer Center), Matthew D. Galsky(Icahn School of Medicine at Mount Sinai), Menggang Yu(University of Michigan), Daniele Raggi(Fondazione IRCCS Istituto Nazionale dei Tumori), Francesco Montorsi(Vita-Salute San Raffaele University), Giuseppe Fallara(Istituti di Ricovero e Cura a Carattere Scientifico), Andrea Necchi(Vita-Salute San Raffaele University), Himanshu Joshi(Icahn School of Medicine at Mount Sinai)
Cited by 12
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k